Ambrisentan, selective endothelin receptor ETa antagonist, in the treatment of pulmonary arterial hypertension

Abstract

Pulmonary arterial hypertension is a primary disorder affecting pulmonary arterioles of either an unknown (idiopathic or hereditary PAH) or a known cause (systemic connective tissue diseases, hepatic disorders, inborn heart defects with a right-to-left shunt, HIV infection, abuse of certain anorectic medication).

Keywords

• Ambrisentan
• pulmonary arterial hypertension
• endothelin receptor antagonists